Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?

The Journal of pathology·2026
Same author

Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.

Breast (Edinburgh, Scotland)·2026
Same author

Editorial: Immune-related biomarkers in skin and breast cancer: innovations in immunological diagnostics and therapies.

Frontiers in immunology·2026
Same author

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Minerva urology and nephrology·2026
Same author

Impact of Driver Genetic Alterations on Survival in Metastatic Colorectal Cancer Patients from a Genetically Homogeneous Sardinian Population: A Real-World Study.

Cancers·2026
Same author

How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma.

Cells·2026

Related Experiment Video

Updated: Jun 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Riccardo Serra1,2, Emilio Francesco Giunta3, Giuseppe Schepisi2

  • 1Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy.

Expert Review of Anticancer Therapy
|December 24, 2024
PubMed
Summary
This summary is machine-generated.

Combining talazoparib (a PARP inhibitor) with enzalutamide significantly improved progression-free survival in advanced prostate cancer, especially for patients with HRR gene mutations.

Keywords:
HRDHRRPARP inhibitorRB1TMPRSS2-ERGenzalutamidemCRPCtalazoparib

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K

Related Experiment Videos

Last Updated: Jun 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K

Area of Science:

  • Oncology
  • Genitourinary Cancers
  • Cancer Therapeutics

Background:

  • Prostate cancer (PCa) is a leading global cancer in men, often with poor outcomes in advanced stages.
  • Current treatments include androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).

Purpose of the Study:

  • To review the clinical efficacy, safety, and future potential of combining talazoparib (a PARPi) with enzalutamide (an AR antagonist).
  • To assess the findings of the TALAPRO-2 trial regarding this combination therapy.

Main Methods:

  • Evaluation of clinical data from the TALAPRO-2 trial.
  • Analysis of treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients.

Main Results:

  • The combination therapy demonstrated significant improvement in radiographic progression-free survival (rPFS).
  • Benefit was particularly noted in patients with Homologous Recombination Repair (HRR) gene mutations, including BRCA1/2.
  • Emerging biomarkers like TMPRSS2-ERG and RB1 mutations may predict outcomes in the broader patient population.

Conclusions:

  • The talazoparib and enzalutamide combination shows promise for mCRPC, especially in HRR-mutated cases.
  • Further research is needed to explore non-HRR mutation targets and earlier-stage applications.
  • Refining treatment strategies based on biomarkers is crucial for optimizing combination therapy outcomes.